Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and
renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation …

The peptide hormone relaxin has traditionally been linked to the maternal adaptation of the
cardiovascular system during the first trimester of pregnancy. By promoting nitric oxide …

Fibrosis (organ scarring) is a hallmark of many forms of cardiovascular and renal disease,
and causes organ dysfunction and structural changes when normal tissue is replaced with …

Relaxin is emerging as an important vasodilator of pregnancy and is being tested for
afterload reduction in acute heart failure. However, the mechanisms underlying relaxin …

Relaxin, which is a peptide hormone of the insulin superfamily, is involved in the promotion
of extracellular matrix remodeling. This property is responsible for many well-known …

Fibrosis is a major player in cardiovascular disease, both as a contributor to the
development of disease, as well as a post-injury response that drives progression. Despite …

Since its discovery as a reproductive hormone 80 years ago, relaxin has been implicated in
a number of pregnancy-related functions involving extracellular matrix (ECM) turnover and …

The insulin‐like peptide relaxin, originally identified as a hormone of pregnancy, is now
known to exert a range of pleiotropic effects including vasodilatory, anti‐fibrotic, angiogenic …

Acute heart failure (AHF) is characterized by high morbidity and mortality and high costs.
Although the treatment of AHF has not changed substantially in recent decades, it is …

Early maternal vascular adaptations to pregnancy are predominantly driven by changes in
vascular tone, reactivity, and remodeling. Failure of the maternal systemic vasculature to …